Study of Continuing or Stopping Somatostatin Analog Treatment in Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors Starting Second-Line Therapy
Led by University Hospital, Antwerp · Updated on 2024-06-14
270
Participants Needed
19
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of continuing versus stopping somatostatin analog SSA treatment in patients with advanced, non-functional gastroenteropancreatic GEP neuroendocrine tumors NET who have progressive disease despite first-line SSA therapy. This Phase 4, multi-national, open-label, randomized, controlled trial divides eligible patients into two groups based on their second-line therapy choice peptide receptor radionuclide therapy PRRT or targeted therapy. The study aims to understand the impact of continuing SSA treatment alongside second-line therapies, stratifying patients by tumor grade and study site.
CONDITIONS
Brief Title
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Research Team
M
Marc U Peeters, MD
T
Timon Vandamme, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Written informed consent before any study procedures
ECOG performance status of 2 or less
Histologically confirmed diagnosis of locally advanced or metastatic, non-functional, well-differentiated grade 1-2 GEP neuroendocrine tumor
Documented disease progression while on first-line somatostatin analog treatment at label dose or higher
For targeted therapy group: planned to start sunitinib or everolimus as second-line treatment
For PRRT group: planned to start PRRT with Lutetium (177Lu) oxodotreotide as second-line treatment
You will not qualify if you...
Need for chemotherapy as second-line treatment for GEP NET
Presence of poorly differentiated grade 3 neuroendocrine carcinoma or rapidly progressive tumor
Previous treatment with everolimus, sunitinib, or PRRT
Contraindication or allergy to somatostatin analogs or use for other than functional NET
Progressive disease while on lower than registered somatostatin analog dose
Functional neuroendocrine tumor with clinical and biochemical syndrome
Receiving palliative systemic treatment for other cancers
Participation in another investigational anti-cancer trial
Any medical or psychiatric condition that could risk patient safety or study data quality
Pregnant or breastfeeding, or planning pregnancy during treatment phase
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 18 months
Participants receive somatostatin analog treatment every 4 weeks or have the treatment withdrawn for 18 months, depending on their assigned group.
Monthly visits for 18 months
Follow-up
Duration - Up to 6.5 years
Participants are followed for overall survival and quality of life assessments up to 6.5 years after starting second-line treatment.
Periodic visits for assessments during follow-up
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using 68Ga-DOTATOC PET Scans to Evaluate Gastroenteropancreatic Neuroendocrine Tumors in Adults
Observational Study on Treatment Patterns and Outcomes in Adults with Gastroenteropancreatic Neuroendocrine Tumors Using Real-World Claims Data
Study of Continuing or Stopping Somatostatin Analog Treatment in Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors Starting Second-Line Therapy
Prospective Study of Gastroenteropancreatic Neuroendocrine Tumors Treated with Targeted Radionuclide Therapy Using PET-MRI Imaging and AI Analysis
Assessment of Nutritional Status in Adults With Gastroenteropancreatic Neuroendocrine Tumors
Followed at Strasbourg University Hospital
Study of Peptide Receptor Radionuclide Therapy PRRT in Adults with Gastroenteropancreatic Neuroendocrine Tumors
Phase 1 Study of RYZ401, a Radiopharmaceutical Therapy with Actinium-225,
for Neuroendocrine and Other Solid Tumors Expressing Somatostatin Receptors
First-in-Human Study of 212PbVMT--NET Targeted Alpha Therapy for Advanced SSTR2 Positive Tumors Evaluating Dose and Safety
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol.
Siddharth Chhajlani, Jelka Kuiper, Philippe Beutels...